Enzymatica AB: ColdZyme® sales continue to perform well
2016年11月3日 - 5:01PM
Interim report
for
Enzymatica AB (publ)
January-September 2016
ColdZyme® sales
continue to perform well
Q3
- Net sales reached SEK 12.3 (6.8) million.
- Loss after tax came in at SEK -6.5 (-10.1)
million.
- Earnings per share were SEK -0.08 (-0.41).
- Cash and cash equivalents were SEK 49.9 (9.7)
million.
Significant events in Q3
- Enzymatica completed a directed share issue,
raising SEK 40 million before issue expenses.
Significant events after
Q3
- Enzymatica signed exclusive agreements for
Australia, New Zeeland, Greece and Cyprus.
First nine months
- Net sales increased to SEK 25.6 (16.9)
million.
- Loss after tax came in at SEK -27.4 (-29.6)
million.
- Earnings per share were SEK -0.49
(-1.19).
Financial ratios |
|
|
|
|
|
(SEK million) |
Q3
2016 |
Q3
2015 |
Jan-Sep
2016 |
Jan-Sep
2015 |
Full year
2015 |
Net
sales |
12.3 |
6.8 |
25.6 |
16.9 |
27.9 |
Gross
margin, % |
66 |
67 |
64 |
73 |
70 |
Operating
profit/loss |
-7.7 |
-9.9 |
-27.6 |
-29.4 |
-40.5 |
Cash flow
from operating activities |
-15.6 |
-12.7 |
-35.6
|
-25.5 |
-37.7 |
Average
number of employees |
22 |
17 |
20 |
15 |
16 |
(Zymetech is consolidated in Enzymatica's figures
as at April 1, 2016)
CEO statement: Continued sales growth and new
international agreements signed
The Company boasts year-on-year growth of 52% over the first nine
months of the year, with total sales, including sales from
Zymetech, coming in at SEK 25.6 million in comparison to SEK 16.9
million in the corresponding period of the previous year.
Sales in Sweden continue to perform well and in September ColdZyme®
reported a market share of around 7% in the cold segment in spite
of a weak start to the cold season. Growth in September was 81%.
Other established markets are exhibiting satisfactory growth,
except for the UK, where efforts to find a suitable distributor are
in progress. Sales have gotten off to a good start on the Finnish
market which was recently established, while pre-launch work in
Spain is proceeding according to plan, with the expected start of
the cold season in November.
The Company pursued its financing strategy in Q3 by conducting a
directed issue of 17.5 million shares to new long-term and
financially strong owners. The funds raised for the Company by the
issue creates financial stability for the Company's ongoing
international expansion.
Our efforts to reel in excellent distribution partners remain our
highest priority, and we signed a distribution agreement for Greece
and Cyprus in October. This agreement was signed with Life NLB Ltd,
a small company prepared to put in the financial resources and
commitment required to establish ColdZyme on these markets.
Yesterday we signed a distribution agreement with Endeavour
Consumer Health, Australia's largest distributor to pharmacies and
the third largest in New Zealand. It is also our first contract in
the southern hemisphere and a step towards a seasonal adjustment.
We expect a launch in the 2018.
As previously announced, we expect to have the final results of our
latest patient study ready by the end of the year. We are on track
to meet higher government requirements in connection with the new
EU legislation for medical devices on time. Adoption of the new
legislation is expected early next year.
We enter the final chapter of 2016 with a boost from our sales
growth and a rise in demand for our product on the
Scandinavian market.
Fredrik Lindberg,
CEO
Enzymatica at a
glance
Enzymatica AB is a life science company whose business concept is
to develop medical devices based on barrier technology and marine
enzymes for self-care in major market segments. The Company
developed ColdZyme®, a unique
mouth spray for fighting colds, launched the product on seven
markets and reached a position over the past winter as one of the
most-sold cold products in Swedish pharmacies measured in SEK.
Enzymatica has its own sales organization in Scandinavia and
collaborates with a contract sales organization in the UK.
Enzymatica also sells via distributers in Finland and Spain.
Our development focuses on medical devices for
upper respiratory tract infections and oral health. An enzyme from
deep-sea fish is a key sub-component in product development.
Enzymatica was founded in 2007, has its head
office in Lund and has been listed on the Nasdaq First North since
June 15, 2015.
For questions about this report,
please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
Bengt Jöndell, Interim CFO, Enzymatica
AB
Tel: +46 (0)703-77 71 70 | Email: bengt.jondell@enzymatica.com
Enzymatica Interim Report
January-September 2016
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 9 2024 まで 10 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
過去 株価チャート
から 10 2023 まで 10 2024